Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 5;11:2206. doi: 10.1038/s41467-020-16067-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Genes with germline pathogenic/likely pathogenic (P/LP) variants in known cancer-predisposing genes (KCPG) and candidate genes and their type of alterations in children, adolescents, and young adult (C-AYA) patients with solid tumors. b Oncoplots of top mutated genes with P/LP variants in KCPG and candidate genes based on the age group. Each column represents one patient and its affected genes. c Two examples of copy number variations (CNVs) found in C-AYA patients with solid tumors. d The number of patients with germline alterations, both single-nucleotide variations (SNVs) and CNVs, in each tumor type. e Clinical outcome comparison between two groups of C-AYA patients with solid tumors, with and without germline alterations. Gray color represents the number of patients with the specified clinical outcome in each group. Two-sided Fisher's exact test was implemented, P = 0.31, OR = 2.14, 95% CI = 0.6–8.0. ACT adrenocortical carcinoma, CNS central nervous system, EWS Ewing sarcoma, GCT germ cell tumor, HGG high-grade glioma, LGG low-grade glioma, LMPRT low malignancy potential renal tumor, NBL neuroblastoma, NM non-malignant tumor, OS osteosarcoma, RCC renal cell carcinoma, RHB rhabdomyosarcoma, STS soft tissue sarcoma, WLM Wilms tumor, Del deletion, Ins insertion.